In Simple Terms
A group representing U.S. drug companies spent about $59 million on search ads from 2019 to 2025. Many ads focused on health insurance and pharmacy benefit managers, whom drug companies blame for high prices. The numbers show a major effort to influence what people see online, but they do not prove that the ads changed anyone’s mind.
A Big Spend on a Small Patch of Search Results
According to an analysis published in Clinical Pharmacology & Therapeutics, the U.S. trade group Pharmaceutical Research and Manufacturers of America (PhRMA) spent an estimated $59 million on search advertising between 2019 and 2025. That puts the debate over drug prices not only in legislation and public statements, but also in the digital spaces people turn to when looking for information about medicines and insurance.
The study estimated that the ads were tied to more than 283,500 different keywords and generated 17.1 million paid visits to landing pages. A keyword is a word or phrase that may be connected to someone’s search, prompting an ad to appear alongside the results. A paid visit means that an ad brought someone to a page or website through this kind of promotion. The figure does not mean that 17.1 million different people saw the ads: the data count visits, not unique individuals.
The sheer number of keywords gives a sense of how broad the activity was, but it does not reveal the message each person saw or whether they read the material after arriving at a page. A search phrase may lead to an ad and a related page, but clicks and visits are not the same as persuasion. The figures therefore shed light on the campaign’s scale and reach, but they cannot, on their own, show how much it influenced public opinion.
Insurance and Pharmacy Benefit Managers in the Spotlight
The estimated spending falls into two broad categories. About $32 million went to ads related to searches for insurance and health plans. Another $28 million was spent directing users to pages and websites critical of pharmacy benefit managers, commonly known as PBMs. Drug companies portray PBMs as responsible for the high prices of many medicines.
These figures call for careful reading: the analysis describes both amounts as approximate, and together they add up to $60 million, while the reported overall total is about $59 million. That is not necessarily a contradiction. Rounded estimates may not add up to a total calculated by a different method or with greater precision. The important point is not to treat the figures as exact accounting totals down to the last dollar.
The broader significance lies in how the dispute is framed. Rather than leaving the discussion at the general question of why drug prices are rising, these campaigns bring insurance, health plans, and pharmacy benefit managers into the picture. They highlight drug companies’ claim that PBMs are behind the rising cost of many medicines. That is the position advanced by the pharmaceutical industry, not an independent finding that one party alone explains drug prices or bears full responsibility for them.
It is also important to distinguish money spent on ads from money spent creating the content audiences encounter. The analysis says some of the spending bought visibility in search results, while some directed visitors to pages criticizing PBMs. But the available information does not detail the contents of every page, the budget for producing them, or how much users paid for medicines after seeing them. Any conclusions should stay within what the data actually measure.
Spending Rose Around Major Policy Moments
Spending did not necessarily follow the same pace throughout the seven years. The analysis says advertising activity increased around legislative and regulatory events that drew wide attention. One example was the start of Medicare drug-price negotiations in 2023. The timing suggests that paid advertising may become more prominent when government decisions about medicines are at the center of public debate.
But timing alone does not prove that any one decision caused every increase in spending, nor does it show exactly how much of the rise was linked to the 2023 negotiations. The available information indicates that spending rose around major public developments; it does not establish a precise cause-and-effect relationship between each event and each dollar spent. That distinction matters: an increase around a particular time should not be turned into a firm causal conclusion that the published figures do not support.
Even so, the timing helps explain the communication strategy. When the political or regulatory landscape around drug prices shifts, the words people use to search for information can become a way to reach them. Search ads let an advertiser try to appear at the moment someone is interested in a topic, rather than waiting for that person to encounter a general message elsewhere. In that sense, a campaign is shaped not only by what it says, but also by when it appears and what people are looking for.
What Do the Visits Show—and What Don’t They?
A total of 17.1 million paid visits is striking, but it should not be read like an opinion poll. A visit measures a person’s arrival at a page, not a change in their views or their acceptance of a particular explanation for drug prices. Someone may open a page and leave, read it without being persuaded, or visit it more than once. The information presented here does not measure whether people remembered the messages or whether the ads affected patients’ choices or policymakers’ decisions.
The overall figure also does not show how visits were divided among different keywords, or between pages related to insurance and those criticizing pharmacy benefit managers. The reported information does not tell us which search terms brought in the most visits, which groups engaged with the pages, or whether visits led to discussion, sharing, or changes in behavior. These are different questions from how much was spent, and answering them would require data beyond the figures presented.
Still, the measures offer a tangible sense of the investment in reaching an audience: tens of millions of dollars, hundreds of thousands of keywords, and millions of visits. And this activity stretched across seven years, from 2019 through 2025, making it more than a brief campaign tied to a single week or decision. But the length of the period does not show that the strategy remained constant throughout; the analysis itself points to increases around major public events.
Why This Matters to People Who Take Medicines
Drug prices have practical consequences for anyone who needs treatment: How much does the patient pay? What role does their health plan play? Which groups help shape the path from a medicine’s price to its final cost? As different players in the industry compete to explain the problem, people may encounter competing stories that assign responsibility in different places. Search ads can make one account more visible, but frequent exposure does not automatically make it complete or accurate.
That is why it matters to know who is behind a message and to distinguish verifiable information from a position advanced by an interested party. In the case examined by the analysis, the spender was a group representing the pharmaceutical industry, and some of the pages promoted by the ads criticized pharmacy benefit managers. Those facts help readers put the messages in context, without deciding on their own whether every accusation is true or false.
The data also serve as a reminder that online reach does not prove that audiences understood the issue. Someone may arrive at a page about insurance or PBMs, but clear information is still needed to explain what the figures mean, what their limits are, and where description ends and advocacy for an organization’s interests begins. The spending analysis adds another layer to the debate: Who pays to make certain messages appear when people search for a sensitive subject?
How to Read the Numbers Fairly
The findings are based on an analysis that used data to model advertising spending, as the report describes it. It is therefore more accurate to treat the $59 million as an estimate than as a confirmed total taken from publicly available accounts. The available information does not name the research team or a specific research institution behind the work, but it does identify the journal in which the analysis appeared: Clinical Pharmacology & Therapeutics. Staying within these limits avoids adding details about the study that were not provided.
There is also an arithmetic and methodological detail worth noting: the breakdown of about $32 million for ads related to insurance and health plans, and about $28 million for pages critical of pharmacy benefit managers, gives an approximate sum that exceeds the estimated total by $1 million. Because the amounts are approximate, they should be reported as given, with their estimated nature made clear, rather than changing one of them or claiming that they match exactly. Journalistic accuracy does not mean hiding the difference; it means explaining it calmly.
From the same perspective, the keyword and visit counts describe advertising activity, not the quality of the information each person received. They do not show on their own whether the pages were balanced or effective, and they do not prove that search ads changed public opinion of drug companies or pharmacy benefit managers. What they do show is that the competition to explain drug costs took a structured digital form, with paid search visibility playing a substantial part.
The Bottom Line
The analysis paints a picture of major spending on search ads about drug prices in the United States: about $59 million from 2019 to 2025, more than 283,500 keywords, and 17.1 million paid visits. Estimated spending focused on insurance and health plans, at about $32 million, and on pages criticizing pharmacy benefit managers, at about $28 million. Activity also rose around major public events, including the start of Medicare drug-price negotiations in 2023. These measures show how the pharmaceutical industry is trying to shape the online debate, but they do not prove that the ads persuaded the public or settle who is responsible for high prices. They measure the scale of an effort to influence the discussion, not its ultimate effect.